Shorter Time to Discontinuation Due to Treatment Failure in People Living with HIV Switched to Dolutegravir Plus Either Rilpivirine or Lamivudine Compared with Integrase Inhibitor-Based Triple Therapy in a Large Spanish Cohort
Open Access
- 11 April 2022
- journal article
- research article
- Published by Springer Nature in Infectious Diseases and Therapy
- Vol. 11 (3) , 1177-1192
Abstract
Introduction Standard therapy for HIV treatment has consisted of two nucleoside analogue reverse transcriptase inhibitors (NRTI) paired with a third agent. Use of two-drug regimens (2DR) has been considered for selected patients in part to avoid toxicities associated with the use of NRTIs. This study aimed to compare the real-world outcomes of integrase inhibitor (INSTI)-based three-drug regimens (3DR) versus 2DR of dolutegravir (DTG) + rilpivirine (RPV) or DTG + lamivudine (3TC). Methods All patients in the Spanish VACH cohort switching to INSTI-based 3DR or a 2DR consisting of DTG + RPV or DTG + 3TC between May 2, 2016 and May 15, 2019 were included. Kaplan–Meier curves and Cox proportional hazard models were used to assess time to/risk of discontinuation due to treatment failure (TF) (defined as virologic failure [VF], immunologic failure, or disease progression) and adverse events (AEs). Three secondary analyses were performed: (1) in restricting the analysis to patients who were virologically suppressed (HIV RNA < 50 copies/mL) at switch; (2) matched analysis (2:1, matched by age, sex, number of previous VFs, and line of regimen), and (3) using VF as the primary endpoint in all patients. Results Overall, 5047 3DR and 617 2DR patients were analyzed. Baseline characteristics differed between groups; 2DR patients were older, more treatment experienced, and more likely to be virologically suppressed at switch. Time to discontinuation due to TF was significantly shorter for 2DR (P = 0.002). The hazard ratio (HR) for discontinuation due to TF on 2DR vs 3DR was 2.33 (P = 0.003). No difference was observed for time to discontinuation (P = 0.908) or risk of discontinuation due to AEs (HR = 0.80; P = 0.488). Results were qualitatively similar in virologically suppressed patients, matched analysis, and for VF. Conclusion In the real world, the risks of discontinuation due to TF and VF were more than two times higher in patients switching to DTG-based 2DR than INSTI-based 3DR, with no difference in discontinuation due to AEs.Keywords
Funding Information
- Gilead Sciences
This publication has 42 references indexed in Scilit:
- Adherence Profiles and Therapeutic Responses of Treatment-Naive HIV-Infected Patients Starting Boosted Atazanavir-Based Therapy in the ANRS 134-COPHAR 3 TrialAntimicrobial Agents and Chemotherapy, 2013
- The natural history of HIV infectionCurrent Opinion in HIV and AIDS, 2013
- Relationship between minority nonnucleoside reverse transcriptase inhibitor resistance mutations, adherence, and the risk of virologic failureAIDS, 2012
- Levels of Adherence Required for Virologic Suppression Among Newer Antiretroviral MedicationsAnnals of Pharmacotherapy, 2011
- History of viral suppression on combination antiretroviral therapy as a predictor of virological failure after a treatment change*HIV Medicine, 2010
- Abacavir and risk of myocardial infarction in HIV‐infected patients on highly active antiretroviral therapy: a population‐based nationwide cohort studyHIV Medicine, 2010
- A randomized trial of two-drug versus three-drug tenofovir-containing maintenance regimens in virologically controlled HIV-1 patientsJournal of Antimicrobial Chemotherapy, 2009
- Epidemiological trends of HIV infection in SpainAIDS, 2002
- Determinants of Virological Response to Antiretroviral Therapy: Implications for Long-Term StrategiesClinical Infectious Diseases, 2000
- A Trial Comparing Nucleoside Monotherapy with Combination Therapy in HIV-Infected Adults with CD4 Cell Counts from 200 to 500 per Cubic MillimeterNew England Journal of Medicine, 1996